Therapy Areas: Cardiovascular
Innovent Biologics presents preclinical data for IL-6/TL1A bispecific antibody IAR177
13 November 2026 - Innovent Biologics, Inc. (HKEX: 01801), a China-based biopharmaceutical company that develops, manufactures, and commercialises medicines for the treatment of oncology, autoimmune, ...
Energenesis Biomedical presents ENERGI-based approach to space anaemia at TASTI 2026
10 November 2026 - Energenesis Biomedical Co Ltd (TWSE:6657), a clinical-stage biopharmaceutical company focused on restoring cellular energy, announced on Monday that it presented at the Taiwan Space...
Pentixapharm advances preparationsfor Phase 3 PANDA study
4 November 2026 - Biotechnology company Pentixapharm Holding AG (Frankfurt Prime Standard: PTP) on Wednesday reported further progress towards its pivotal Phase 3 PANDA study, with US ethics approval ...
Abbott's Amulet 360 shows high LAA closure rates and low stroke incidence at one year
2 November 2026 - Healthcare company Abbott (NYSE: ABT) reported on Monday that it has achieved positive one-year results from the pivotal VERITAS study of its investigational Amulet 360 Left Atrial A...
Abbott reports 30-day results from clinical trial of SonicForce Coronary IVL System
2 November 2026 - US healthcare company Abbott (NYSE:ABT) on Sunday reported strong 30-day results from the TECTONIC Coronary Artery Disease (CAD) Intravascular Lithotripsy (IVL) Investigational Devic...
Daiichi Sankyo secures EMA validation for two triple-combination cholesterol therapies
29 October 2026 - Japanese healthcare company Daiichi Sankyo Co Ltd (TYO:4568) announced on Thursday that it has received European Medicines Agency (EMA) validation for two marketing authorisation app...